Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial.

PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial. Ann Hematol. 2004; 83 Suppl 1:S89-90.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.